Results 131 to 140 of about 15,116 (246)
Apathy in Parkinson's Disease: Distinguishing Overlapping Symptoms Via Network Analysis
Movement Disorders Clinical Practice, EarlyView.Abstract Background Anxiety, fatigue, and excessive daytime sleepiness (EDS) frequently co‐occur in Parkinson's disease (PD) and can influence the clinical determination of apathy. Objective To distinguish patient‐reported apathy from other non‐motor symptoms.
Joseph Seemiller +6 more
wiley +1 more source
Wearable Sweat Band for Noninvasive Levodopa Monitoring
, 2019 Levodopa is the standard medication clinically prescribed to patients afflicted with Parkinson’s disease. In particular, the monitoring and optimization of levodopa dosage are critical to mitigate the onset of undesired fluctuations in the patients ...
Tiffany S. Liaw (7181891) +25 more
core +1 more source
, 2017 Background: Levodopa bioavailability is enhanced by adding entacapone. However, the optimal dose of levodopa while transitioning to levodopa/carbidopa/entacapone (LCE) in Parkinson's disease (PD) during the wearing-off period is unclear.
이필휴, 손영호
core +1 more source
Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases
Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre +5 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for Parkinson's disease (PD). Using 7‐Tesla (7 T) MRI connectivity analysis to visualize the patient‐specific STN motor subdivision, we hypothesize that reprogramming patients who are stimulated outside of this subdivision can improve their ...
Yarit Wiggerts +6 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background New sophisticated deep brain stimulation (DBS) systems enabling steering of current and aiming at improving further motor outcome and decreasing side effects have virtually replaced old omnidirectional systems, despite being more labor‐intensive and expensive.
Marwan Hariz, Patric Blomstedt
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background 22q11.2 deletion syndrome (22q11DS) is a multisystem genetic disorder associated with a significantly increased risk of early‐onset Parkinson's disease (EOPD). Management is challenging because psychiatric and cognitive comorbidities often limit advanced therapies such as deep brain stimulation (DBS). Cases We report 2 patients with
Valle Victor Andrés +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Subthalamic nucleus deep brain stimulation (STN DBS) improves Parkinson's disease (PD)‐related motor symptoms, but how STN DBS impacts various aspects of patient‐perceived health‐related quality of life (HRQoL) is less clear. The Patient‐Reported Outcome Measurement Instrument (PROMIS) and Quality of Life in Neurological Disorders ...
Sarah A. Brinkerhoff +10 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida +4 more
wiley +1 more source
Movement Disorders Clinical Practice, EarlyView.Abstract Background Parkinson's disease (PD) progression is highly heterogeneous, complicating clinical management and prognostication. While machine learning models have been developed using research datasets such as Parkinson's Precision Medicine Initiative (PPMI) and Parkinson's Disease Biomarkers Program (PDBP), their clinical translatability is ...
Xuehua Ye +9 more
wiley +1 more source